SREBF1 and fatty liver disease: In these BL6-centered studies, mouse models of NASH can be broadly subdivided into (i) severe NASH and liver fibrosis in the absence of features of the metabolic syndrome (e.g., methionine choline deficient (MCD) diet, SREBP1c TG or PPARα-/-), or (ii) hepatic steatosis with presence of metabolic dysfunction but in the absence of NASH and / or liver fibrosis (e.g., high-fat diet (HFD), ob/ob)13.